


Savid Therapeutics, Inc announces publication of data showing pathological complete remission of relapsed tumors highlighting STI-001 a proprietary HER2 targeted photoimmunotherapy drug. September 21, 2022

TOKYO, Japan, September 16, 2022 – Savid Therapeutics, Inc., ("Savid" or the "Company") today announced the Cancer Science publication of an article entitled "Pathological Complete Remission of Relapsed Tumor by Photo-Activating Antibody–Mimetic Drug Conjugate Treatment". The data describes the complete remission of tumors resulting from the relapse of tumor growth after an initial drug treatment. The research was funded by Savid at the University of Tokyo Laboratory for Systems Biology and Medicine.

"We are pleased with the results of this experiment establishing proof that the Savid Cupid-Psyche system is ideal for the delivery of our proprietary photoactivated payload Ax-SiPc. Repeated dosing seems to be well tolerated and very effective in treating relapsed tumors. We look forward to the next series of tests showing the delivery of multiple payloads to a variety of cancer cell targets." said Masanobu Tsukagoshi, Chief Executive Officer at Savid.



The Savid Cupid-Psyche platform is a proprietary antibody mimetic drug conjugate platform that enables targeted delivery of multiple types of therapeutic payloads including photoimmunotherapy, cytotoxic, radioisotope and immune system activating therapeutics to a variety of cancer cell surface antigens. The technology helps to overcome much of the complexity of the biologics manufacturing process with a simple streamlined protein expression process in Escherichia coli requiring no post translational modifications of the compound.

"Savid continues to successfully advance STI-001 the HER2/Ax-SiPc asset described in the current publication in therapies for extramammary Paget's disease and HER2 positive gastric, esophageal and head and neck cancers. Additional candidates in the pipeline include drugs targeting HER1 and CEA positive cancers, and novel targets for hepatocellular carcinoma and pancreatic cancers," said Michael Chansler, Vice President of Business Development at Savid.

Tatsuhiko Kodama, M.D. PhD., inventor of Savid's technology said, "We are very happy with the continued support from our partners and academic researchers as we advance this technology to address many unmet medical needs."

For additional information, visit www.savidtherapeutics.com.

Contact Savid: info@savidtherapeutics.com